Skip to main content

Table 2 Univariate analyses of factors associated with OS and DFS in all surgical patients

From: Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases

 

OS

DFS

 

HR

95 % CI

p

HR

95 % CI

p

Age >65 years

5.12

2.34–11.9

<0.001

1.37

0.80–2.33

0.241

Male

1.87

0.89–4.31

0.100

1.18

0.70–2.04

0.538

Synchronous disease

2.45

1.14–5.85

0.021

1.50

0.87–2.65

0.141

Conversion disease

1.56

0.36–4.75

0.504

1.99

1.02–3.70

0.0435

Node-positive primary tumor

1.43

0.67–2.99

0.342

1.30

0.77–2.26

0.333

Rectum

0.83

0.37–1.74

0.897

1.11

0.71–1.92

0.709

Adjuvant chemotherapy

0.78

0.36–1.61

0.506

0.90

0.50–1.53

0.693

No. of liver metastases ≥5

1.43

0.63–3.06

0.164

2.18

1.23–3.79

0.0076

Maximum tumor size >5 cm

1.32

0.48–3.15

0.555

1.99

1.04–3.56

0.0375

CA19-9 ≥100 U/mL

1.40

0.55–3.13

0.457

1.46

0.77–2.63

0.235

R1 resection

1.07

0.51–2.17

0.853

1.15

0.68–1.96

0.597

  1. OS overall survival, DFS disease-free survival, HR hazard ratio, CI confidence interval